APO Research
Talk to an analyst

APO RESEARCH · REPORT

Expectorant Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Expectorant Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchExpectorant Drug Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Expectorant Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Expectorant Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Expectorant Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Expectorant Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Expectorant Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Expectorant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Expectorant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Expectorant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Expectorant Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Expectorant Drug include Sanofi SA, lohnson and Johnson, Merck KGaA, Pfizer Inc., GlaxoSmithKline plc., Astrazeneca Plc., Vernalis plc, Tris Pharma Inc. and The Himalaya Drug Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Expectorant Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Expectorant Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Expectorant Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Expectorant Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Expectorant Drug Segment by Company

Sanofi SA

lohnson and Johnson

Merck KGaA

Pfizer Inc.

GlaxoSmithKline plc.

Astrazeneca Plc.

Vernalis plc

Tris Pharma Inc.

The Himalaya Drug Company

Taro Pharmaceutical Industries Ltd.

Reckitt Benckiser Group plc

Proctor and Gamble Co

Perrigo Company plc

Novartis International AG

Mayne Pharma Inc.

Glenmark Pharmaceuticals Limited

Dabur India Ltd

Cipla Limited

Aytu BioScience Inc.

Aurobindo Pharma Ltd

Amneal Pharmaceuticals LLC

Acella Pharmaceuticals LLC

Abbott Laboratories

Expectorant Drug Segment by Type

Inhalants

Oral Liquid

Oral Solid

Expectorant Drug Segment by Application

Hospital

Clinic

Other

Expectorant Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Expectorant Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Expectorant Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Expectorant Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Expectorant Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Expectorant Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Expectorant Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Expectorant Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Expectorant Drug Industry Trends Table 2. Expectorant Drug Industry Drivers Table 3. Expectorant Drug Industry Opportunities and Challenges Table 4. Expectorant Drug Industry Restraints Table 5. Global Expectorant Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Expectorant Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Expectorant Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Expectorant Drug Sales Market Share by Manufacturers Table 9. Global Expectorant Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Expectorant Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Expectorant Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Expectorant Drug Manufacturers, Product Type & Application Table 13. Global Expectorant Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Expectorant Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Inhalants Table 17. Major Manufacturers of Oral Liquid Table 18. Major Manufacturers of Oral Solid Table 19. Global Expectorant Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Expectorant Drug Sales by Type (2021-2026) & (k units) Table 21. Global Expectorant Drug Sales by Type (2027-2032) & (k units) Table 22. Global Expectorant Drug Sales Market Share by Type (2021-2026) Table 23. Global Expectorant Drug Sales Market Share by Type (2027-2032) Table 24. Global Expectorant Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Expectorant Drug Revenue by Type (2021-2026) & (k units) Table 26. Global Expectorant Drug Revenue by Type (2027-2032) & (k units) Table 27. Global Expectorant Drug Revenue Market Share by Type (2021-2026) Table 28. Global Expectorant Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Other Table 32. Global Expectorant Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Expectorant Drug Sales by Application (2021-2026) & (k units) Table 34. Global Expectorant Drug Sales by Application (2027-2032) & (k units) Table 35. Global Expectorant Drug Sales Market Share by Application (2021-2026) Table 36. Global Expectorant Drug Sales Market Share by Application (2027-2032) Table 37. Global Expectorant Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Expectorant Drug Revenue by Application (2021-2026) & (k units) Table 39. Global Expectorant Drug Revenue by Application (2027-2032) & (k units) Table 40. Global Expectorant Drug Revenue Market Share by Application (2021-2026) Table 41. Global Expectorant Drug Revenue Market Share by Application (2027-2032) Table 42. Global Expectorant Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Expectorant Drug Sales by Region (2021-2026) & (k units) Table 44. Global Expectorant Drug Sales Market Share by Region (2021-2026) Table 45. Global Expectorant Drug Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Expectorant Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Expectorant Drug Sales by Country (2021-2026) & (k units) Table 49. North America Expectorant Drug Sales by Country (2027-2032) & (k units) Table 50. Europe Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Expectorant Drug Sales by Country (2021-2026) & (k units) Table 52. Europe Expectorant Drug Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Expectorant Drug Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Expectorant Drug Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Expectorant Drug Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Expectorant Drug Sales by Country (2027-2032) & (k units) Table 59. Global Expectorant Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Expectorant Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Expectorant Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Expectorant Drug Revenue Market Share by Region (2021-2026) Table 63. Global Expectorant Drug Revenue Market Share by Region (2027-2032) Table 64. Sanofi SA Company Information Table 65. Sanofi SA Business Overview Table 66. Sanofi SA Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sanofi SA Expectorant Drug Product Portfolio Table 68. Sanofi SA Recent Development Table 69. lohnson and Johnson Company Information Table 70. lohnson and Johnson Business Overview Table 71. lohnson and Johnson Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. lohnson and Johnson Expectorant Drug Product Portfolio Table 73. lohnson and Johnson Recent Development Table 74. Merck KGaA Company Information Table 75. Merck KGaA Business Overview Table 76. Merck KGaA Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck KGaA Expectorant Drug Product Portfolio Table 78. Merck KGaA Recent Development Table 79. Pfizer Inc. Company Information Table 80. Pfizer Inc. Business Overview Table 81. Pfizer Inc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Inc. Expectorant Drug Product Portfolio Table 83. Pfizer Inc. Recent Development Table 84. GlaxoSmithKline plc. Company Information Table 85. GlaxoSmithKline plc. Business Overview Table 86. GlaxoSmithKline plc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc. Expectorant Drug Product Portfolio Table 88. GlaxoSmithKline plc. Recent Development Table 89. Astrazeneca Plc. Company Information Table 90. Astrazeneca Plc. Business Overview Table 91. Astrazeneca Plc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Astrazeneca Plc. Expectorant Drug Product Portfolio Table 93. Astrazeneca Plc. Recent Development Table 94. Vernalis plc Company Information Table 95. Vernalis plc Business Overview Table 96. Vernalis plc Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Vernalis plc Expectorant Drug Product Portfolio Table 98. Vernalis plc Recent Development Table 99. Tris Pharma Inc. Company Information Table 100. Tris Pharma Inc. Business Overview Table 101. Tris Pharma Inc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Tris Pharma Inc. Expectorant Drug Product Portfolio Table 103. Tris Pharma Inc. Recent Development Table 104. The Himalaya Drug Company Company Information Table 105. The Himalaya Drug Company Business Overview Table 106. The Himalaya Drug Company Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. The Himalaya Drug Company Expectorant Drug Product Portfolio Table 108. The Himalaya Drug Company Recent Development Table 109. Taro Pharmaceutical Industries Ltd. Company Information Table 110. Taro Pharmaceutical Industries Ltd. Business Overview Table 111. Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Taro Pharmaceutical Industries Ltd. Expectorant Drug Product Portfolio Table 113. Taro Pharmaceutical Industries Ltd. Recent Development Table 114. Reckitt Benckiser Group plc Company Information Table 115. Reckitt Benckiser Group plc Business Overview Table 116. Reckitt Benckiser Group plc Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Reckitt Benckiser Group plc Expectorant Drug Product Portfolio Table 118. Reckitt Benckiser Group plc Recent Development Table 119. Proctor and Gamble Co Company Information Table 120. Proctor and Gamble Co Business Overview Table 121. Proctor and Gamble Co Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Proctor and Gamble Co Expectorant Drug Product Portfolio Table 123. Proctor and Gamble Co Recent Development Table 124. Perrigo Company plc Company Information Table 125. Perrigo Company plc Business Overview Table 126. Perrigo Company plc Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Perrigo Company plc Expectorant Drug Product Portfolio Table 128. Perrigo Company plc Recent Development Table 129. Novartis International AG Company Information Table 130. Novartis International AG Business Overview Table 131. Novartis International AG Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Novartis International AG Expectorant Drug Product Portfolio Table 133. Novartis International AG Recent Development Table 134. Mayne Pharma Inc. Company Information Table 135. Mayne Pharma Inc. Business Overview Table 136. Mayne Pharma Inc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Mayne Pharma Inc. Expectorant Drug Product Portfolio Table 138. Mayne Pharma Inc. Recent Development Table 139. Glenmark Pharmaceuticals Limited Company Information Table 140. Glenmark Pharmaceuticals Limited Business Overview Table 141. Glenmark Pharmaceuticals Limited Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Glenmark Pharmaceuticals Limited Expectorant Drug Product Portfolio Table 143. Glenmark Pharmaceuticals Limited Recent Development Table 144. Dabur India Ltd Company Information Table 145. Dabur India Ltd Business Overview Table 146. Dabur India Ltd Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Dabur India Ltd Expectorant Drug Product Portfolio Table 148. Dabur India Ltd Recent Development Table 149. Cipla Limited Company Information Table 150. Cipla Limited Business Overview Table 151. Cipla Limited Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Cipla Limited Expectorant Drug Product Portfolio Table 153. Cipla Limited Recent Development Table 154. Aytu BioScience Inc. Company Information Table 155. Aytu BioScience Inc. Business Overview Table 156. Aytu BioScience Inc. Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Aytu BioScience Inc. Expectorant Drug Product Portfolio Table 158. Aytu BioScience Inc. Recent Development Table 159. Aurobindo Pharma Ltd Company Information Table 160. Aurobindo Pharma Ltd Business Overview Table 161. Aurobindo Pharma Ltd Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Aurobindo Pharma Ltd Expectorant Drug Product Portfolio Table 163. Aurobindo Pharma Ltd Recent Development Table 164. Amneal Pharmaceuticals LLC Company Information Table 165. Amneal Pharmaceuticals LLC Business Overview Table 166. Amneal Pharmaceuticals LLC Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 167. Amneal Pharmaceuticals LLC Expectorant Drug Product Portfolio Table 168. Amneal Pharmaceuticals LLC Recent Development Table 169. Acella Pharmaceuticals LLC Company Information Table 170. Acella Pharmaceuticals LLC Business Overview Table 171. Acella Pharmaceuticals LLC Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 172. Acella Pharmaceuticals LLC Expectorant Drug Product Portfolio Table 173. Acella Pharmaceuticals LLC Recent Development Table 174. Abbott Laboratories Company Information Table 175. Abbott Laboratories Business Overview Table 176. Abbott Laboratories Expectorant Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 177. Abbott Laboratories Expectorant Drug Product Portfolio Table 178. Abbott Laboratories Recent Development Table 179. Key Raw Materials Table 180. Raw Materials Key Suppliers Table 181. Expectorant Drug Distributors List Table 182. Expectorant Drug Customers List Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Expectorant Drug Product Image Figure 2. Global Expectorant Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Expectorant Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Expectorant Drug Sales (2021-2032) & (k units) Figure 5. Global Expectorant Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Expectorant Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Inhalants Image Figure 9. Oral Liquid Image Figure 10. Oral Solid Image Figure 11. Global Expectorant Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Expectorant Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Expectorant Drug Sales Market Share by Type (2021-2032) Figure 14. Global Expectorant Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Expectorant Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Expectorant Drug Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Expectorant Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Expectorant Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Expectorant Drug Sales Market Share by Application (2021-2032) Figure 23. Global Expectorant Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Expectorant Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Expectorant Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Expectorant Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Expectorant Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Expectorant Drug Sales Market Share by Country (2021-2032) Figure 40. China Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Expectorant Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Expectorant Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Expectorant Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Expectorant Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Expectorant Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Expectorant Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Expectorant Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Expectorant Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Expectorant Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Expectorant Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Inhalants
  • Oral Liquid
  • Oral Solid
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Sanofi SA
  • lohnson and Johnson
  • Merck KGaA
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Astrazeneca Plc.
  • Vernalis plc
  • Tris Pharma Inc.
  • The Himalaya Drug Company
  • Taro Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Proctor and Gamble Co
  • Perrigo Company plc
  • Novartis International AG
  • Mayne Pharma Inc.
  • Glenmark Pharmaceuticals Limited
  • Dabur India Ltd
  • Cipla Limited
  • Aytu BioScience Inc.
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals LLC
  • Acella Pharmaceuticals LLC
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Expectorant Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Expectorant Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Expectorant Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Expectorant Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Expectorant Drug Market Dynamics
  1. 2.1 Expectorant Drug Industry Trends
  2. 2.2 Expectorant Drug Industry Drivers
  3. 2.3 Expectorant Drug Industry Opportunities and Challenges
  4. 2.4 Expectorant Drug Industry Restraints
3 Expectorant Drug Market by Manufacturers
  1. 3.1 Global Expectorant Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Expectorant Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Expectorant Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Expectorant Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Expectorant Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Expectorant Drug Manufacturers, Product Type & Application
  7. 3.7 Global Expectorant Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Expectorant Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Expectorant Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Expectorant Drug Tier 1, Tier 2, and Tier 3
4 Expectorant Drug Market by Type
  1. 4.1 Expectorant Drug Type Introduction
  2. 4.1.1 Inhalants
  3. 4.1.2 Oral Liquid
  4. 4.1.3 Oral Solid
  5. 4.2 Global Expectorant Drug Sales by Type
  6. 4.2.1 Global Expectorant Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Expectorant Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Expectorant Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Expectorant Drug Revenue by Type
  10. 4.3.1 Global Expectorant Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Expectorant Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Expectorant Drug Revenue Market Share by Type (2021-2032)
5 Expectorant Drug Market by Application
  1. 5.1 Expectorant Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Expectorant Drug Sales by Application
  6. 5.2.1 Global Expectorant Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Expectorant Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Expectorant Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Expectorant Drug Revenue by Application
  10. 5.3.1 Global Expectorant Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Expectorant Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Expectorant Drug Revenue Market Share by Application (2021-2032)
6 Global Expectorant Drug Sales by Region
  1. 6.1 Global Expectorant Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Expectorant Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Expectorant Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Expectorant Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Expectorant Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Expectorant Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Expectorant Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Expectorant Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Expectorant Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Expectorant Drug Revenue by Region
  1. 7.1 Global Expectorant Drug Revenue by Region
  2. 7.1.1 Global Expectorant Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Expectorant Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Expectorant Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Expectorant Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Expectorant Drug Revenue (2021-2032)
  8. 7.2.2 North America Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Expectorant Drug Revenue (2021-2032)
  11. 7.3.2 Europe Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Expectorant Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Expectorant Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Expectorant Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi SA
  2. 8.1.1 Sanofi SA Company Information
  3. 8.1.2 Sanofi SA Business Overview
  4. 8.1.3 Sanofi SA Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi SA Expectorant Drug Product Portfolio
  6. 8.1.5 Sanofi SA Recent Developments
  7. 8.2 lohnson and Johnson
  8. 8.2.1 lohnson and Johnson Company Information
  9. 8.2.2 lohnson and Johnson Business Overview
  10. 8.2.3 lohnson and Johnson Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 lohnson and Johnson Expectorant Drug Product Portfolio
  12. 8.2.5 lohnson and Johnson Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Expectorant Drug Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Expectorant Drug Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 GlaxoSmithKline plc.
  26. 8.5.1 GlaxoSmithKline plc. Company Information
  27. 8.5.2 GlaxoSmithKline plc. Business Overview
  28. 8.5.3 GlaxoSmithKline plc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc. Expectorant Drug Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc. Recent Developments
  31. 8.6 Astrazeneca Plc.
  32. 8.6.1 Astrazeneca Plc. Company Information
  33. 8.6.2 Astrazeneca Plc. Business Overview
  34. 8.6.3 Astrazeneca Plc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Astrazeneca Plc. Expectorant Drug Product Portfolio
  36. 8.6.5 Astrazeneca Plc. Recent Developments
  37. 8.7 Vernalis plc
  38. 8.7.1 Vernalis plc Company Information
  39. 8.7.2 Vernalis plc Business Overview
  40. 8.7.3 Vernalis plc Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vernalis plc Expectorant Drug Product Portfolio
  42. 8.7.5 Vernalis plc Recent Developments
  43. 8.8 Tris Pharma Inc.
  44. 8.8.1 Tris Pharma Inc. Company Information
  45. 8.8.2 Tris Pharma Inc. Business Overview
  46. 8.8.3 Tris Pharma Inc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Tris Pharma Inc. Expectorant Drug Product Portfolio
  48. 8.8.5 Tris Pharma Inc. Recent Developments
  49. 8.9 The Himalaya Drug Company
  50. 8.9.1 The Himalaya Drug Company Company Information
  51. 8.9.2 The Himalaya Drug Company Business Overview
  52. 8.9.3 The Himalaya Drug Company Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 The Himalaya Drug Company Expectorant Drug Product Portfolio
  54. 8.9.5 The Himalaya Drug Company Recent Developments
  55. 8.10 Taro Pharmaceutical Industries Ltd.
  56. 8.10.1 Taro Pharmaceutical Industries Ltd. Company Information
  57. 8.10.2 Taro Pharmaceutical Industries Ltd. Business Overview
  58. 8.10.3 Taro Pharmaceutical Industries Ltd. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Taro Pharmaceutical Industries Ltd. Expectorant Drug Product Portfolio
  60. 8.10.5 Taro Pharmaceutical Industries Ltd. Recent Developments
  61. 8.11 Reckitt Benckiser Group plc
  62. 8.11.1 Reckitt Benckiser Group plc Company Information
  63. 8.11.2 Reckitt Benckiser Group plc Business Overview
  64. 8.11.3 Reckitt Benckiser Group plc Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Reckitt Benckiser Group plc Expectorant Drug Product Portfolio
  66. 8.11.5 Reckitt Benckiser Group plc Recent Developments
  67. 8.12 Proctor and Gamble Co
  68. 8.12.1 Proctor and Gamble Co Company Information
  69. 8.12.2 Proctor and Gamble Co Business Overview
  70. 8.12.3 Proctor and Gamble Co Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Proctor and Gamble Co Expectorant Drug Product Portfolio
  72. 8.12.5 Proctor and Gamble Co Recent Developments
  73. 8.13 Perrigo Company plc
  74. 8.13.1 Perrigo Company plc Company Information
  75. 8.13.2 Perrigo Company plc Business Overview
  76. 8.13.3 Perrigo Company plc Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Perrigo Company plc Expectorant Drug Product Portfolio
  78. 8.13.5 Perrigo Company plc Recent Developments
  79. 8.14 Novartis International AG
  80. 8.14.1 Novartis International AG Company Information
  81. 8.14.2 Novartis International AG Business Overview
  82. 8.14.3 Novartis International AG Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Novartis International AG Expectorant Drug Product Portfolio
  84. 8.14.5 Novartis International AG Recent Developments
  85. 8.15 Mayne Pharma Inc.
  86. 8.15.1 Mayne Pharma Inc. Company Information
  87. 8.15.2 Mayne Pharma Inc. Business Overview
  88. 8.15.3 Mayne Pharma Inc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mayne Pharma Inc. Expectorant Drug Product Portfolio
  90. 8.15.5 Mayne Pharma Inc. Recent Developments
  91. 8.16 Glenmark Pharmaceuticals Limited
  92. 8.16.1 Glenmark Pharmaceuticals Limited Company Information
  93. 8.16.2 Glenmark Pharmaceuticals Limited Business Overview
  94. 8.16.3 Glenmark Pharmaceuticals Limited Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Glenmark Pharmaceuticals Limited Expectorant Drug Product Portfolio
  96. 8.16.5 Glenmark Pharmaceuticals Limited Recent Developments
  97. 8.17 Dabur India Ltd
  98. 8.17.1 Dabur India Ltd Company Information
  99. 8.17.2 Dabur India Ltd Business Overview
  100. 8.17.3 Dabur India Ltd Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dabur India Ltd Expectorant Drug Product Portfolio
  102. 8.17.5 Dabur India Ltd Recent Developments
  103. 8.18 Cipla Limited
  104. 8.18.1 Cipla Limited Company Information
  105. 8.18.2 Cipla Limited Business Overview
  106. 8.18.3 Cipla Limited Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Cipla Limited Expectorant Drug Product Portfolio
  108. 8.18.5 Cipla Limited Recent Developments
  109. 8.19 Aytu BioScience Inc.
  110. 8.19.1 Aytu BioScience Inc. Company Information
  111. 8.19.2 Aytu BioScience Inc. Business Overview
  112. 8.19.3 Aytu BioScience Inc. Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Aytu BioScience Inc. Expectorant Drug Product Portfolio
  114. 8.19.5 Aytu BioScience Inc. Recent Developments
  115. 8.20 Aurobindo Pharma Ltd
  116. 8.20.1 Aurobindo Pharma Ltd Company Information
  117. 8.20.2 Aurobindo Pharma Ltd Business Overview
  118. 8.20.3 Aurobindo Pharma Ltd Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Aurobindo Pharma Ltd Expectorant Drug Product Portfolio
  120. 8.20.5 Aurobindo Pharma Ltd Recent Developments
  121. 8.21 Amneal Pharmaceuticals LLC
  122. 8.21.1 Amneal Pharmaceuticals LLC Company Information
  123. 8.21.2 Amneal Pharmaceuticals LLC Business Overview
  124. 8.21.3 Amneal Pharmaceuticals LLC Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Amneal Pharmaceuticals LLC Expectorant Drug Product Portfolio
  126. 8.21.5 Amneal Pharmaceuticals LLC Recent Developments
  127. 8.22 Acella Pharmaceuticals LLC
  128. 8.22.1 Acella Pharmaceuticals LLC Company Information
  129. 8.22.2 Acella Pharmaceuticals LLC Business Overview
  130. 8.22.3 Acella Pharmaceuticals LLC Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Acella Pharmaceuticals LLC Expectorant Drug Product Portfolio
  132. 8.22.5 Acella Pharmaceuticals LLC Recent Developments
  133. 8.23 Abbott Laboratories
  134. 8.23.1 Abbott Laboratories Company Information
  135. 8.23.2 Abbott Laboratories Business Overview
  136. 8.23.3 Abbott Laboratories Expectorant Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Abbott Laboratories Expectorant Drug Product Portfolio
  138. 8.23.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Expectorant Drug Value Chain Analysis
  2. 9.1.1 Expectorant Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Expectorant Drug Production Mode & Process
  6. 9.2 Expectorant Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Expectorant Drug Distributors
  9. 9.2.3 Expectorant Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst